Skip to main content

Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010

Buy Article:

$50.00 plus tax (Refund Policy)


A baseline serotype distribution was established by age and region for 2058 invasive Streptococcus pneumoniae isolates collected during the implementation period of the 13-valent pneumococcal conjugate vaccine (PCV13) program in many parts of Canada in 2010. Serotypes 19A, 7F, and 3 were the most prevalent in all age groups, accounting for 57% in <2 year olds, 62% in 2–4 year olds, 45% in 5–14 year olds, 44% in 15–49 year olds, 41% in 50–64 year olds, and 36% in ≥65 year olds. Serotype 19A was most predominant in Western and Central Canada representing 15% and 22%, respectively, of the isolates from those regions, whereas 7F was most common in Eastern Canada with 20% of the isolates. Other prevalent serotypes include 15A, 23B, 12F, 22F, and 6C. PCV13 serotypes represented 65% of the pneumococci isolated from <2 year olds, 71% of 2–4 year olds, 61% of 5–14 year olds, 60% of 15–49 year olds, 53% of 50–64 year olds, and 49% of the ≥65 year olds. Continued monitoring of invasive pneumococcal serotypes in Canada is important to identify epidemiological trends and assess the impact of the newly introduced PCV13 vaccine on public health.

Keywords: PCV13; Streptococcus pneumoniae; infection pneumococcique invasive; invasive pneumococcal disease; serotype; surveillance; sérotype

Document Type: Research Article


Affiliations: 1: National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB R3E 3R2, Canada. 2: Laboratoire de santé publique du Québec, 20045 chemin Sainte-Marie, Ste-Anne-de-Bellevue, QC H9X 3R5, Canada. 3: Toronto Invasive Bacterial Diseases Network, Department of Microbiology, Mount Sinai Hospital, 600 University Avenue, Room 210, Toronto, ON M5G 1X5, Canada. 4: Vaccine Preventable Diseases Section, Surveillance and Outbreak Response Division, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Room 273A, 2nd Floor, 130 Colonnade Road, AL 6502A, Ottawa, ON K1A 0K9, Canada. 5: Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. 6: Provincial Laboratory for Public Health (Microbiology), Walter Mackenzie Health Sciences Centre, 8440 - 112 Street, Edmonton, AB T6G 2J2, Canada.

Publication date: 2012-08-23

More about this publication?
  • Published since 1954, this monthly journal contains new research in the field of microbiology including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more